Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Cardiff Oncology, Inc. (NASDAQ:CRDF) has been given an average rating of “Moderate Buy” by the six ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $11.1250.

A number of research analysts have issued reports on CRDF shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Cardiff Oncology in a research report on Wednesday, October 8th. Noble Financial began coverage on shares of Cardiff Oncology in a research note on Monday, January 5th. They set an “outperform” rating and a $12.00 target price on the stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Jeppson Wealth Management LLC bought a new position in shares of Cardiff Oncology in the 3rd quarter worth approximately $25,000. Brooklyn Investment Group bought a new position in Cardiff Oncology in the third quarter worth $26,000. Baader Bank Aktiengesellschaft purchased a new position in Cardiff Oncology during the second quarter valued at $32,000. Belpointe Asset Management LLC bought a new stake in shares of Cardiff Oncology during the 1st quarter valued at $37,000. Finally, Integrity Alliance LLC. purchased a new stake in shares of Cardiff Oncology in the 2nd quarter worth about $41,000. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Cardiff Oncology Stock Performance

NASDAQ CRDF opened at $3.08 on Friday. The stock has a market cap of $207.47 million, a P/E ratio of -3.90 and a beta of 1.40. Cardiff Oncology has a fifty-two week low of $1.90 and a fifty-two week high of $4.99. The stock has a 50 day simple moving average of $2.46 and a two-hundred day simple moving average of $2.59.

Cardiff Oncology (NASDAQ:CRDF) last announced its earnings results on Thursday, November 6th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.03. Cardiff Oncology had a negative return on equity of 77.21% and a negative net margin of 10,064.27%.The company had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.12 million. Sell-side analysts predict that Cardiff Oncology will post -0.99 earnings per share for the current year.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.